Patents by Inventor Robert Zelle
Robert Zelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100267697Abstract: The present teachings provide compounds of Formula (I) and pharmaceutically acceptable salts, hydrates, and esters thereof, wherein Ar, R1, R2, R3, p, and X are defined herein. The present teachings also provide processes for producing said compounds and their pharmaceutically acceptable salts, hydrates and esters, and methods of treating a pathological condition or disorder, or alleviating a symptom thereof, using said compounds including their pharmaceutically acceptable salts, hydrates and esters. The compounds can be useful in modulating ion channel activity including treating a variety of conditions associated with the abnormal modulation of one or more voltage-gated calcium channels.Type: ApplicationFiled: December 11, 2007Publication date: October 21, 2010Applicant: WyethInventors: Vincent P. Galullo, Robert Zelle, Danielle Soenen, Christopher Todd Baker, Paul Will, Hormoz Mazdiyasni, Jinsong Guo, Andrew Fensome, Jeffrey Curtis Kern, William Jay Moore, Edward George Melenski, Justin Kaplan
-
Publication number: 20100029716Abstract: The present invention relates to a novel derivative of Compound 1 selectively substituted with fluorine and/or deuterium and optionally further substituted with deuterium and 13C elsewhere in the molecule. The compounds of this invention are cholesterol esterase transfer protein inhibitors and possess unique biopharmaceutical and pharmacokinetic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and tissues and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these compounds and methods of treating diseases and conditions that are responsive to inhibition of cholesterol esterase transfer protein, alone and in combination with additional agents.Type: ApplicationFiled: April 10, 2007Publication date: February 4, 2010Applicant: CONCERT PHARMACEUTICALS, INC.Inventors: Roger Tung, Robert Zelle
-
Patent number: 7547717Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: GrantFiled: March 7, 2005Date of Patent: June 16, 2009Assignee: WyethInventors: Robert Zelle, Vincent P. Galullo
-
Publication number: 20090012095Abstract: This invention features a method for modulating human N-type calcium channel ?1B+SFVG subunit activity.Type: ApplicationFiled: April 29, 2008Publication date: January 8, 2009Applicant: WyethInventors: Robert Zelle, Pravin Chaturvedi
-
Publication number: 20080293722Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 15, 2005Publication date: November 27, 2008Applicant: WyethInventors: Robert Zelle, Christopher Todd Baker, Paul Will, Vincent P. Galullo
-
Publication number: 20080242716Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: October 2, 2008Inventors: Robert Zelle, Christopher T. Baker
-
Publication number: 20080139560Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: June 12, 2008Inventors: Robert Zelle, Vincent P. Galullo
-
Patent number: 7368467Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: GrantFiled: March 7, 2005Date of Patent: May 6, 2008Assignee: WyethInventors: Robert Zelle, Vincent P. Galullo, Hormoz Mazdiyasni
-
Publication number: 20080090891Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: December 12, 2007Publication date: April 17, 2008Applicant: WyethInventors: Robert Zelle, Vincent Galullo, Hormoz Mazdiyasni
-
Publication number: 20080039449Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1? converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-?-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-?-mediated diseases and decreasing IGIF and IFN-? production using the compounds and compositions of this invention.Type: ApplicationFiled: January 18, 2007Publication date: February 14, 2008Inventors: Mark Batchelor, David Bebbington, Guy Bemis, Wolf Fridman, Roger Gillespie, Julian Golec, David Lauffer, David Livingston, Saroop Matharu, Michael Mullican, Mark Murcko, Robert Murdoch, Robert Zelle
-
Publication number: 20070281937Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: December 6, 2007Inventors: Robert Zelle, Vincent Galullo, Christopher Baker, Paul Will, William Frazee, Hormoz Mazdiyasni, Jinsong Guo
-
Publication number: 20070208064Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: September 6, 2007Applicant: WyethInventors: Robert Zelle, Vincent Galullo, Paul Will
-
Publication number: 20070208070Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: September 6, 2007Inventors: Robert Zelle, Vincent Galullo
-
Publication number: 20070203194Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein cab be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: August 30, 2007Applicants: SCION PHARMACEUTICALS, INC., WYETHInventors: Robert Zelle, Vincent Galullo, Christopher Baker, Paul Will, William Frazee
-
Publication number: 20070197513Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: August 23, 2007Inventor: Robert Zelle
-
Publication number: 20070197619Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: August 23, 2007Inventors: Robert Zelle, Paul Will
-
Publication number: 20070191448Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: August 16, 2007Inventors: Robert Zelle, Vincent Galullo
-
Publication number: 20050203159Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 7, 2005Publication date: September 15, 2005Inventors: Robert Zelle, Vincent Galullo, Hormoz Mazdiyasni
-
Publication number: 20050143436Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1? converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-?-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-?-mediated diseases and decreasing IGIF and IFN-? production using the compounds and compositions of this invention.Type: ApplicationFiled: November 29, 2004Publication date: June 30, 2005Inventors: Mark Batchelor, David Bebbington, Guy Bemis, Wolf Fridman, Roger Gillespie, Julian Golec, David Lauffer, David Livingston, Saroop Matharu, Michael Mullican, Mark Murcko, Robert Murdoch, Robert Zelle
-
Publication number: 20040204404Abstract: This invention features a method for modulating human N-type calcium channel &agr;1B+SFVG subunit activity.Type: ApplicationFiled: September 29, 2003Publication date: October 14, 2004Inventors: Robert Zelle, Pravin Chaturvedi